Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-TTX-MC138
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
64Cu-TTX-MC138 is a radiolabeled diagnostic imaging agent developed by TransCode Therapeutics for the early detection of metastatic cancer using Positron Emission Tomography (PET). It is a derivative of the therapeutic candidate TTX-MC138, which consists of an iron oxide nanoparticle conjugated to antagomirs targeting microRNA-10b (miR-10b), a key driver of metastasis. In the diagnostic version, the nanoparticle is tagged with the radioisotope copper-64 (64Cu) through a NODAGA chelator, enabling highly sensitive and specific quantitative determination of its pharmacokinetics and biodistribution. This allows for the non-invasive observation of delivery to metastatic lesions. A Phase 0 clinical trial has provided evidence of its ability to reach metastatic sites and demonstrate pharmacodynamic activity.
- Other names
- 64Cu-labeled TTX-MC138
02
Targets
miR-10b (MicroRNA 10b)
Beyond the preview
Go deeper on 64Cu-TTX-MC138.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-TTX-MC138.